SLDB
Solid Biosciences Inc
NASDAQ · Biotechnology
$6.52
+0.29 (+4.65%)
Open$6.40
Previous Close$6.23
Day High$6.63
Day Low$6.35
52W High$7.37
52W Low$2.41
Volume—
Avg Volume964.6K
Market Cap507.97M
P/E Ratio—
EPS$-2.49
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+67.2% upside
Current
$6.52
$6.52
Target
$10.90
$10.90
$9.47
$10.90 avg
$14.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 294.33M | 265.12M | 296.42M |
| Net Income | 32.12M | 33.11M | 29.81M |
| Profit Margin | 10.9% | 12.5% | 10.1% |
| EBITDA | 56.98M | 46.74M | 49.34M |
| Free Cash Flow | 40.15M | 38.44M | 35.75M |
| Rev Growth | +16.9% | -8.0% | -9.5% |
| Debt/Equity | 0.34 | 0.27 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |